The charter is being launched for consultation in the wake of CMC’s CBD in the UK report which was published in June this year. Photo: iStock

UK’s CBD industry has unveiled a new quality charter to help foster the legal compliance in the nascent sector.

The Cannabinoid Industry Quality Charter, released today by the industry body Centre for Medical Cannabis (CMC) for consultation, provides a framework of legal compliance and quality controls.

The charter follows the CMC’s market report which found that many CBD products on the market did not contain what was indicated on the label.

The charter’s legal compliance pathway is mainly focused on Novel Foods authorisation which will be delivered through a new partnership between the CMC and Global Regulatory Services.

“As we have long advocated, the doors have closed for the current approach used by some manufacturers by claiming that the rules are somehow different for the cannabis industry,” said Dr Andy Yates, CMC pharmacy lead.

“This new initiative exists to ensure that our members are fully compliant to an agreed set of terms with the relevant regulatory bodies, ensuring consumers can continue to access legal, safe and quality CBD products.”

The new charter’s seven pillars cover legal frameworks, testing, labelling, manufacturing, controlled drugs, marketing ethics, and sustainability and social impact.

The CMC said it will work with the Food Standards Agency and the European Food Safety Agency on Novel Foods or other applicable authorisations once the charter attracts sufficient signatories.

“Our goal is to provide the leadership required to work alongside policy-makers, regulators, producers and retailers to achieve the shared goal of an innovative, responsible, high quality and legally compliant sector,” said Steve Moore, CMC founder and director.

“Our new charter will enable us to deliver on this.”

 


Warning: A non-numeric value encountered in /home/pharm77/public_html/wp-content/themes/pharmacy/includes/wp_booster/td_block.php on line 308

LEAVE A REPLY